 Edward Ashwood
Concepts (364)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prenatal Diagnosis | 14 | 2021 | 194 | 1.360 |
Why?
| | Amniotic Fluid | 16 | 2006 | 87 | 1.110 |
Why?
| | Antigens, Fungal | 4 | 2011 | 28 | 0.980 |
Why?
| | Histoplasma | 3 | 2009 | 12 | 0.900 |
Why?
| | Immunoenzyme Techniques | 4 | 2009 | 212 | 0.880 |
Why?
| | Laboratories | 8 | 2020 | 108 | 0.770 |
Why?
| | Fetal Organ Maturity | 14 | 2004 | 27 | 0.720 |
Why?
| | Histoplasmosis | 3 | 2011 | 14 | 0.710 |
Why?
| | Trisomy | 4 | 2020 | 77 | 0.580 |
Why?
| | Chemistry, Clinical | 6 | 2014 | 12 | 0.550 |
Why?
| | Pathology, Clinical | 7 | 2014 | 36 | 0.540 |
Why?
| | Bilirubin | 3 | 2006 | 96 | 0.530 |
Why?
| | Down Syndrome | 9 | 2021 | 477 | 0.520 |
Why?
| | Aspartate Aminotransferases | 1 | 2015 | 88 | 0.480 |
Why?
| | Alanine Transaminase | 1 | 2015 | 153 | 0.460 |
Why?
| | Fetal Diseases | 2 | 2013 | 158 | 0.440 |
Why?
| | Clinical Laboratory Techniques | 5 | 2013 | 94 | 0.440 |
Why?
| | DNA | 4 | 2020 | 1404 | 0.440 |
Why?
| | Pathology | 2 | 2010 | 22 | 0.430 |
Why?
| | Chromosome Disorders | 1 | 2013 | 40 | 0.420 |
Why?
| | alpha 1-Antitrypsin Deficiency | 5 | 2013 | 67 | 0.410 |
Why?
| | Lung | 14 | 2004 | 3938 | 0.410 |
Why?
| | Liver Diseases | 1 | 2015 | 290 | 0.400 |
Why?
| | alpha-Fetoproteins | 6 | 2013 | 42 | 0.370 |
Why?
| | Pregnancy | 28 | 2021 | 6417 | 0.360 |
Why?
| | Phosphatidylcholines | 12 | 2001 | 145 | 0.360 |
Why?
| | Medical Laboratory Personnel | 1 | 2010 | 7 | 0.360 |
Why?
| | Serpins | 1 | 2010 | 31 | 0.340 |
Why?
| | Antibodies, Fungal | 1 | 2009 | 9 | 0.330 |
Why?
| | Fluorescence Polarization | 10 | 1994 | 38 | 0.330 |
Why?
| | alpha 1-Antitrypsin | 4 | 2013 | 107 | 0.320 |
Why?
| | Sphingomyelins | 11 | 2001 | 29 | 0.320 |
Why?
| | Delivery of Health Care | 2 | 2015 | 898 | 0.310 |
Why?
| | Pancreatic Function Tests | 1 | 2008 | 3 | 0.300 |
Why?
| | Pancreatic Elastase | 1 | 2008 | 60 | 0.300 |
Why?
| | Specimen Handling | 7 | 2002 | 162 | 0.290 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 308 | 0.280 |
Why?
| | Neural Tube Defects | 3 | 2021 | 59 | 0.270 |
Why?
| | Chloroform | 1 | 2006 | 4 | 0.270 |
Why?
| | Pancreas | 1 | 2008 | 303 | 0.250 |
Why?
| | Feces | 1 | 2008 | 442 | 0.240 |
Why?
| | Humans | 78 | 2024 | 129625 | 0.230 |
Why?
| | Phosphatidylglycerols | 6 | 2001 | 24 | 0.210 |
Why?
| | Biomarkers, Tumor | 1 | 2010 | 1164 | 0.210 |
Why?
| | Renin | 1 | 2003 | 32 | 0.210 |
Why?
| | Pulmonary Surfactants | 3 | 2004 | 106 | 0.210 |
Why?
| | Reagent Kits, Diagnostic | 5 | 2015 | 43 | 0.200 |
Why?
| | Rabbits | 3 | 2009 | 779 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 834 | 0.190 |
Why?
| | Creatinine | 4 | 2013 | 490 | 0.190 |
Why?
| | Reference Values | 6 | 2013 | 794 | 0.180 |
Why?
| | Internship and Residency | 4 | 2014 | 1050 | 0.180 |
Why?
| | Quality Control | 5 | 2008 | 163 | 0.180 |
Why?
| | Reproducibility of Results | 13 | 2015 | 3080 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2020 | 32 | 0.160 |
Why?
| | Phospholipids | 4 | 2001 | 216 | 0.160 |
Why?
| | Vaccines | 1 | 2024 | 400 | 0.150 |
Why?
| | Blood Specimen Collection | 4 | 2003 | 35 | 0.140 |
Why?
| | Female | 35 | 2021 | 68734 | 0.140 |
Why?
| | Laboratories, Hospital | 3 | 2013 | 14 | 0.140 |
Why?
| | Fluorescent Dyes | 6 | 1993 | 312 | 0.140 |
Why?
| | Clinical Laboratory Information Systems | 3 | 1992 | 6 | 0.140 |
Why?
| | Amniocentesis | 5 | 2013 | 23 | 0.140 |
Why?
| | Phenotype | 4 | 2013 | 3075 | 0.140 |
Why?
| | Referral and Consultation | 2 | 2014 | 730 | 0.140 |
Why?
| | Lead | 1 | 1997 | 56 | 0.130 |
Why?
| | Hepacivirus | 3 | 2005 | 239 | 0.130 |
Why?
| | Utah | 3 | 2014 | 64 | 0.130 |
Why?
| | Photosensitivity Disorders | 1 | 1996 | 8 | 0.130 |
Why?
| | Capillaries | 1 | 1997 | 103 | 0.130 |
Why?
| | Vitamin B 12 | 1 | 1997 | 122 | 0.130 |
Why?
| | Porphyrins | 1 | 1996 | 21 | 0.130 |
Why?
| | Cryopreservation | 1 | 1997 | 94 | 0.130 |
Why?
| | Folic Acid | 1 | 1997 | 184 | 0.130 |
Why?
| | Clinical Laboratory Services | 1 | 2015 | 8 | 0.120 |
Why?
| | Blood Chemical Analysis | 2 | 2008 | 97 | 0.120 |
Why?
| | Altitude | 1 | 2000 | 462 | 0.120 |
Why?
| | United States | 13 | 2021 | 13871 | 0.120 |
Why?
| | Maternal Serum Screening Tests | 1 | 2015 | 3 | 0.120 |
Why?
| | Aneuploidy | 1 | 2015 | 92 | 0.110 |
Why?
| | Hepatitis, Viral, Human | 2 | 2007 | 25 | 0.110 |
Why?
| | Curriculum | 2 | 2006 | 920 | 0.110 |
Why?
| | Infant, Newborn | 10 | 2008 | 5756 | 0.110 |
Why?
| | Blood Preservation | 1 | 1997 | 271 | 0.110 |
Why?
| | Legislation, Medical | 1 | 2013 | 11 | 0.100 |
Why?
| | Abortion, Induced | 1 | 2015 | 100 | 0.100 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 1993 | 13 | 0.100 |
Why?
| | Evaluation Studies as Topic | 7 | 2000 | 175 | 0.100 |
Why?
| | Government Regulation | 1 | 2013 | 49 | 0.100 |
Why?
| | Isoquinolines | 1 | 1993 | 41 | 0.100 |
Why?
| | Pregnancy Trimester, Second | 2 | 2021 | 77 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2013 | 152 | 0.100 |
Why?
| | Neuromuscular Junction | 1 | 1993 | 58 | 0.100 |
Why?
| | Medical Informatics | 1 | 1993 | 99 | 0.100 |
Why?
| | Genetic Testing | 2 | 2015 | 430 | 0.100 |
Why?
| | Embryonic and Fetal Development | 1 | 1992 | 95 | 0.100 |
Why?
| | Automation | 2 | 2002 | 81 | 0.100 |
Why?
| | Chlorine | 1 | 1992 | 59 | 0.100 |
Why?
| | Sensitivity and Specificity | 7 | 2013 | 1843 | 0.100 |
Why?
| | Mass Spectrometry | 2 | 2011 | 714 | 0.100 |
Why?
| | Software Validation | 1 | 1992 | 9 | 0.100 |
Why?
| | Observer Variation | 3 | 2009 | 314 | 0.100 |
Why?
| | Arsenic | 1 | 1992 | 63 | 0.100 |
Why?
| | Chlorides | 1 | 1992 | 139 | 0.090 |
Why?
| | RNA, Viral | 4 | 2005 | 620 | 0.090 |
Why?
| | Proteinuria | 1 | 2011 | 92 | 0.090 |
Why?
| | Glomerular Filtration Rate | 2 | 2013 | 712 | 0.090 |
Why?
| | Inclusion Bodies | 2 | 2001 | 23 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2024 | 851 | 0.090 |
Why?
| | Consultants | 1 | 2011 | 13 | 0.090 |
Why?
| | Fluorescence Polarization Immunoassay | 1 | 1990 | 2 | 0.090 |
Why?
| | Pregnancy Complications | 2 | 1993 | 493 | 0.090 |
Why?
| | Hospitals | 1 | 2015 | 637 | 0.090 |
Why?
| | Adult | 15 | 2015 | 35599 | 0.090 |
Why?
| | Materials Testing | 1 | 1992 | 342 | 0.080 |
Why?
| | Prenatal Care | 1 | 1992 | 277 | 0.080 |
Why?
| | History, 21st Century | 1 | 2010 | 186 | 0.080 |
Why?
| | Inhibins | 2 | 2013 | 45 | 0.080 |
Why?
| | Fetal Monitoring | 1 | 1989 | 15 | 0.080 |
Why?
| | False Positive Reactions | 2 | 2007 | 115 | 0.080 |
Why?
| | Pathology, Surgical | 1 | 2009 | 8 | 0.080 |
Why?
| | Chromatography, Liquid | 1 | 2011 | 423 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 133 | 0.080 |
Why?
| | Mass Screening | 2 | 2015 | 1190 | 0.080 |
Why?
| | Water-Electrolyte Balance | 1 | 1988 | 34 | 0.080 |
Why?
| | Nickel | 1 | 1988 | 54 | 0.070 |
Why?
| | Interprofessional Relations | 1 | 2011 | 277 | 0.070 |
Why?
| | Ion Channels | 1 | 1988 | 133 | 0.070 |
Why?
| | Pregnancy Trimester, First | 2 | 2021 | 137 | 0.070 |
Why?
| | Kidney Tubules | 1 | 1988 | 114 | 0.070 |
Why?
| | Oxygen | 1 | 1992 | 915 | 0.070 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 2004 | 103 | 0.070 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 566 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2007 | 20 | 0.070 |
Why?
| | Clinical Chemistry Tests | 1 | 2006 | 11 | 0.070 |
Why?
| | Gestational Age | 5 | 2013 | 876 | 0.070 |
Why?
| | Reference Standards | 2 | 2004 | 176 | 0.070 |
Why?
| | Pediatrics | 2 | 2006 | 1056 | 0.060 |
Why?
| | Solvents | 1 | 2006 | 108 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 398 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 347 | 0.060 |
Why?
| | Child | 8 | 2013 | 20884 | 0.060 |
Why?
| | Conflict of Interest | 1 | 2007 | 123 | 0.060 |
Why?
| | Proteins | 1 | 2011 | 944 | 0.060 |
Why?
| | Actins | 2 | 2007 | 411 | 0.060 |
Why?
| | Animals | 9 | 2009 | 35391 | 0.060 |
Why?
| | Child, Preschool | 5 | 2013 | 10490 | 0.060 |
Why?
| | Data Collection | 2 | 2005 | 650 | 0.060 |
Why?
| | Hepatitis B virus | 1 | 2005 | 36 | 0.060 |
Why?
| | Algorithms | 2 | 2013 | 1616 | 0.060 |
Why?
| | Infant | 4 | 2013 | 8995 | 0.060 |
Why?
| | Hematologic Tests | 1 | 2004 | 22 | 0.060 |
Why?
| | Monte Carlo Method | 2 | 2015 | 143 | 0.050 |
Why?
| | Hyperbilirubinemia | 1 | 2003 | 11 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 217 | 0.050 |
Why?
| | Blood Gas Analysis | 1 | 1983 | 71 | 0.050 |
Why?
| | Mathematics | 1 | 1983 | 102 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2003 | 57 | 0.050 |
Why?
| | Middle Aged | 7 | 2015 | 31136 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 949 | 0.050 |
Why?
| | Central Nervous System Diseases | 1 | 2003 | 69 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 569 | 0.050 |
Why?
| | Risk | 3 | 2007 | 855 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2008 | 1366 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2001 | 14 | 0.050 |
Why?
| | Aged | 5 | 2013 | 22061 | 0.050 |
Why?
| | Postoperative Complications | 1 | 1993 | 2477 | 0.050 |
Why?
| | Sarcoidosis | 1 | 2003 | 156 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2001 | 57 | 0.040 |
Why?
| | Isoelectric Focusing | 2 | 2013 | 34 | 0.040 |
Why?
| | Acute Disease | 2 | 2007 | 979 | 0.040 |
Why?
| | Immunoassay | 1 | 2001 | 107 | 0.040 |
Why?
| | Young Adult | 3 | 2013 | 12455 | 0.040 |
Why?
| | HIV Seropositivity | 1 | 2001 | 119 | 0.040 |
Why?
| | Maternal Age | 2 | 2013 | 125 | 0.040 |
Why?
| | Genotype | 4 | 2007 | 1833 | 0.040 |
Why?
| | Prospective Studies | 5 | 1993 | 7135 | 0.040 |
Why?
| | Trisomy 13 Syndrome | 1 | 2020 | 3 | 0.040 |
Why?
| | Trisomy 18 Syndrome | 1 | 2020 | 6 | 0.040 |
Why?
| | Adolescent | 4 | 2013 | 20412 | 0.040 |
Why?
| | Estriol | 2 | 2013 | 8 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 602 | 0.040 |
Why?
| | Chorionic Gonadotropin | 2 | 2013 | 79 | 0.040 |
Why?
| | Autoantibodies | 1 | 2007 | 1468 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2007 | 1035 | 0.040 |
Why?
| | Time Factors | 3 | 1997 | 6555 | 0.040 |
Why?
| | Health Personnel | 1 | 2024 | 653 | 0.040 |
Why?
| | Hepatitis C | 1 | 2000 | 243 | 0.040 |
Why?
| | Syndrome | 1 | 1998 | 340 | 0.040 |
Why?
| | Predictive Value of Tests | 4 | 2005 | 1947 | 0.030 |
Why?
| | Centrifugation | 2 | 1988 | 30 | 0.030 |
Why?
| | Drug Storage | 1 | 1997 | 57 | 0.030 |
Why?
| | Hand Disinfection | 1 | 1997 | 23 | 0.030 |
Why?
| | History, 20th Century | 1 | 1998 | 294 | 0.030 |
Why?
| | Drug Stability | 1 | 1997 | 159 | 0.030 |
Why?
| | Veins | 1 | 1997 | 60 | 0.030 |
Why?
| | Congresses as Topic | 1 | 1998 | 216 | 0.030 |
Why?
| | Porphobilinogen | 1 | 1996 | 1 | 0.030 |
Why?
| | Uroporphyrins | 1 | 1996 | 1 | 0.030 |
Why?
| | Porphyria Cutanea Tarda | 1 | 1996 | 1 | 0.030 |
Why?
| | Coproporphyrins | 1 | 1996 | 3 | 0.030 |
Why?
| | Male | 7 | 2013 | 63670 | 0.030 |
Why?
| | Membrane Fluidity | 3 | 1990 | 11 | 0.030 |
Why?
| | Coronary Disease | 1 | 1998 | 385 | 0.030 |
Why?
| | Freezing | 2 | 1986 | 87 | 0.030 |
Why?
| | Retrospective Studies | 5 | 2014 | 14522 | 0.030 |
Why?
| | Hospital Administration | 1 | 2015 | 22 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 90 | 0.030 |
Why?
| | HIV-1 | 1 | 2001 | 838 | 0.030 |
Why?
| | Commerce | 1 | 2015 | 67 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2015 | 68 | 0.030 |
Why?
| | Health Care Reform | 1 | 2015 | 101 | 0.030 |
Why?
| | Ampyrone | 1 | 1994 | 1 | 0.030 |
Why?
| | Glycerol Kinase | 1 | 1994 | 1 | 0.030 |
Why?
| | Chromogenic Compounds | 1 | 1994 | 2 | 0.030 |
Why?
| | Phospholipase D | 1 | 1994 | 8 | 0.030 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 1994 | 5 | 0.030 |
Why?
| | Microchemistry | 1 | 1994 | 20 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 580 | 0.030 |
Why?
| | Neutrophils | 2 | 1990 | 1210 | 0.030 |
Why?
| | Pregnancy Trimesters | 1 | 2013 | 16 | 0.030 |
Why?
| | Professional Competence | 1 | 2014 | 95 | 0.030 |
Why?
| | 4-Chloro-7-nitrobenzofurazan | 1 | 1993 | 4 | 0.030 |
Why?
| | Butyrylcholinesterase | 1 | 1993 | 1 | 0.030 |
Why?
| | In Vitro Techniques | 3 | 1990 | 1087 | 0.030 |
Why?
| | Cholinesterases | 1 | 1993 | 10 | 0.030 |
Why?
| | Cytological Techniques | 1 | 1993 | 27 | 0.030 |
Why?
| | Pentoxifylline | 2 | 1990 | 24 | 0.030 |
Why?
| | Vanadium | 1 | 1992 | 4 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2014 | 122 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1990 | 137 | 0.030 |
Why?
| | Abortion, Spontaneous | 1 | 2013 | 100 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 201 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2000 | 1501 | 0.020 |
Why?
| | Albumins | 1 | 1992 | 103 | 0.020 |
Why?
| | Health Care Costs | 1 | 2015 | 367 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 317 | 0.020 |
Why?
| | Systems Analysis | 1 | 1992 | 21 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2013 | 205 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 487 | 0.020 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1990 | 8 | 0.020 |
Why?
| | Virulence Factors, Bordetella | 1 | 1990 | 19 | 0.020 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 16 | 0.020 |
Why?
| | Pertussis Toxin | 1 | 1990 | 26 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2013 | 5415 | 0.020 |
Why?
| | Endothelium, Lymphatic | 1 | 1990 | 12 | 0.020 |
Why?
| | Erythrocyte Membrane | 1 | 1990 | 49 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2011 | 177 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 1994 | 1028 | 0.020 |
Why?
| | Program Development | 2 | 2002 | 355 | 0.020 |
Why?
| | Security Measures | 1 | 1990 | 7 | 0.020 |
Why?
| | Theobromine | 1 | 1989 | 2 | 0.020 |
Why?
| | Information Systems | 1 | 1990 | 61 | 0.020 |
Why?
| | Sodium | 1 | 1990 | 205 | 0.020 |
Why?
| | Calibration | 1 | 1990 | 140 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1990 | 78 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 9786 | 0.020 |
Why?
| | Hemolysis | 1 | 1990 | 199 | 0.020 |
Why?
| | Hypotonic Solutions | 1 | 1988 | 1 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 1991 | 118 | 0.020 |
Why?
| | Blood Protein Electrophoresis | 1 | 2008 | 8 | 0.020 |
Why?
| | Electrophoresis, Capillary | 1 | 2008 | 20 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 1988 | 37 | 0.020 |
Why?
| | Goldfish | 1 | 1988 | 29 | 0.020 |
Why?
| | Particle Size | 1 | 1990 | 351 | 0.020 |
Why?
| | Lymphocytes | 1 | 1990 | 378 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 51 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1990 | 452 | 0.020 |
Why?
| | Sodium Channels | 1 | 1988 | 66 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1988 | 80 | 0.020 |
Why?
| | Biomarkers | 2 | 2013 | 3968 | 0.020 |
Why?
| | Erythrocytes | 1 | 1993 | 673 | 0.020 |
Why?
| | Potassium Channels | 1 | 1988 | 149 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 59 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 693 | 0.020 |
Why?
| | Pregnancy, High-Risk | 1 | 1987 | 14 | 0.020 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 1987 | 9 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 47 | 0.020 |
Why?
| | Proteome | 1 | 2011 | 438 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 388 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 1989 | 391 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 157 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 502 | 0.020 |
Why?
| | Chromatography, Thin Layer | 1 | 1986 | 23 | 0.020 |
Why?
| | Fetus | 1 | 1990 | 774 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 161 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 80 | 0.020 |
Why?
| | Solutions | 1 | 1986 | 150 | 0.020 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 1991 | 601 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 744 | 0.020 |
Why?
| | Amnion | 1 | 1985 | 28 | 0.010 |
Why?
| | Respiration Disorders | 1 | 1986 | 72 | 0.010 |
Why?
| | Cattle | 2 | 2001 | 977 | 0.010 |
Why?
| | Ultracentrifugation | 1 | 2005 | 48 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1202 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 2005 | 69 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 847 | 0.010 |
Why?
| | Hepatitis B | 1 | 2005 | 66 | 0.010 |
Why?
| | Child Health Services | 1 | 2006 | 184 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7052 | 0.010 |
Why?
| | Dimerization | 1 | 2004 | 192 | 0.010 |
Why?
| | Plasma | 1 | 2005 | 205 | 0.010 |
Why?
| | Neonatal Screening | 1 | 2004 | 163 | 0.010 |
Why?
| | Body Temperature | 1 | 1983 | 212 | 0.010 |
Why?
| | Temperature | 1 | 1986 | 637 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1983 | 541 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1017 | 0.010 |
Why?
| | Goats | 1 | 2001 | 26 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 2001 | 63 | 0.010 |
Why?
| | Antibody Specificity | 1 | 2001 | 184 | 0.010 |
Why?
| | Microspheres | 1 | 2001 | 124 | 0.010 |
Why?
| | Blood Glucose | 1 | 1990 | 2100 | 0.010 |
Why?
| | Likelihood Functions | 1 | 2001 | 137 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2001 | 179 | 0.010 |
Why?
| | Butanols | 2 | 1990 | 8 | 0.010 |
Why?
| | Structure-Activity Relationship | 2 | 1990 | 545 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2274 | 0.010 |
Why?
| | Placenta | 1 | 1985 | 723 | 0.010 |
Why?
| | Research Design | 1 | 2004 | 1045 | 0.010 |
Why?
| | Blotting, Western | 1 | 2001 | 1206 | 0.010 |
Why?
| | Sheep | 1 | 2001 | 845 | 0.010 |
Why?
| | Signal Transduction | 1 | 2011 | 4931 | 0.010 |
Why?
| | Cell Movement | 2 | 1990 | 948 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1991 | 3628 | 0.010 |
Why?
| | Chromatography | 1 | 1993 | 25 | 0.010 |
Why?
| | Cell Size | 1 | 1993 | 87 | 0.010 |
Why?
| | Horses | 1 | 1993 | 107 | 0.010 |
Why?
| | Cats | 1 | 1993 | 204 | 0.010 |
Why?
| | Dogs | 1 | 1993 | 383 | 0.010 |
Why?
| | Species Specificity | 1 | 1993 | 574 | 0.010 |
Why?
| | Fee Schedules | 1 | 1991 | 3 | 0.010 |
Why?
| | Melitten | 1 | 1990 | 3 | 0.010 |
Why?
| | Glycols | 1 | 1990 | 6 | 0.010 |
Why?
| | Elapid Venoms | 1 | 1990 | 17 | 0.010 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1990 | 30 | 0.010 |
Why?
| | Germ-Free Life | 1 | 1990 | 33 | 0.010 |
Why?
| | Alcohols | 1 | 1990 | 29 | 0.010 |
Why?
| | Appointments and Schedules | 1 | 1991 | 85 | 0.010 |
Why?
| | 1-Butanol | 1 | 1990 | 2 | 0.010 |
Why?
| | Receptors, Leukocyte-Adhesion | 1 | 1990 | 5 | 0.010 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 1990 | 77 | 0.010 |
Why?
| | Macrophage-1 Antigen | 1 | 1990 | 28 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1990 | 272 | 0.010 |
Why?
| | Plant Proteins | 1 | 1990 | 89 | 0.010 |
Why?
| | Antigens, Differentiation | 1 | 1990 | 82 | 0.010 |
Why?
| | Sodium Chloride | 1 | 1990 | 137 | 0.010 |
Why?
| | Receptors, Concanavalin A | 1 | 1989 | 2 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1990 | 376 | 0.010 |
Why?
| | Lipid Bilayers | 1 | 1990 | 97 | 0.010 |
Why?
| | Mice | 2 | 2001 | 16961 | 0.010 |
Why?
| | Benzimidazoles | 1 | 1990 | 162 | 0.000 |
Why?
| | Catheterization, Peripheral | 1 | 1990 | 104 | 0.000 |
Why?
| | Confidentiality | 1 | 1990 | 67 | 0.000 |
Why?
| | Heparin | 1 | 1990 | 254 | 0.000 |
Why?
| | Regression Analysis | 1 | 1991 | 997 | 0.000 |
Why?
| | Antigens, CD | 1 | 1990 | 487 | 0.000 |
Why?
| | Receptors, Cell Surface | 1 | 1989 | 381 | 0.000 |
Why?
| | Rh Isoimmunization | 1 | 1985 | 2 | 0.000 |
Why?
| | Sex Chromosome Aberrations | 1 | 1985 | 63 | 0.000 |
Why?
| | B-Lymphocytes | 1 | 1990 | 816 | 0.000 |
Why?
| | Models, Biological | 1 | 1990 | 1724 | 0.000 |
Why?
| | Ultrasonography | 1 | 1985 | 712 | 0.000 |
Why?
| | Hemorrhage | 1 | 1985 | 680 | 0.000 |
Why?
| | Mice, Inbred C57BL | 1 | 1990 | 5455 | 0.000 |
Why?
|
|
Ashwood's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|